
Global Endoparasiticide Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Endoparasiticide market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Endoparasiticide market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Endoparasiticide market include Novartis AG, Merck, Eli Lilly, Bayer AG, Zoetis, Virbac, Vetoquinol, Elanco and Ceva Sante Animlae, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Endoparasiticide, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Endoparasiticide, also provides the sales of main regions and countries. Of the upcoming market potential for Endoparasiticide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Endoparasiticide sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Endoparasiticide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Endoparasiticide sales, projected growth trends, production technology, application and end-user industry.
Endoparasiticide Segment by Company
Novartis AG
Merck
Eli Lilly
Bayer AG
Zoetis
Virbac
Vetoquinol
Elanco
Ceva Sante Animlae
Boehringer Ingelheim
Endoparasiticide Segment by Type
Ear Tags
Feed Additives
Tablets
Injectables
Endoparasiticide Segment by Application
Veterinary Hospitals or Clinics
Home Care Settings
Animal Farms
Endoparasiticide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Endoparasiticide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Endoparasiticide market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Endoparasiticide significant trends, drivers, influence factors in global and regions.
6. To analyze Endoparasiticide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endoparasiticide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endoparasiticide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endoparasiticide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Endoparasiticide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endoparasiticide industry.
Chapter 3: Detailed analysis of Endoparasiticide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Endoparasiticide in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Endoparasiticide market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Endoparasiticide market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Endoparasiticide market include Novartis AG, Merck, Eli Lilly, Bayer AG, Zoetis, Virbac, Vetoquinol, Elanco and Ceva Sante Animlae, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Endoparasiticide, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Endoparasiticide, also provides the sales of main regions and countries. Of the upcoming market potential for Endoparasiticide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Endoparasiticide sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Endoparasiticide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Endoparasiticide sales, projected growth trends, production technology, application and end-user industry.
Endoparasiticide Segment by Company
Novartis AG
Merck
Eli Lilly
Bayer AG
Zoetis
Virbac
Vetoquinol
Elanco
Ceva Sante Animlae
Boehringer Ingelheim
Endoparasiticide Segment by Type
Ear Tags
Feed Additives
Tablets
Injectables
Endoparasiticide Segment by Application
Veterinary Hospitals or Clinics
Home Care Settings
Animal Farms
Endoparasiticide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Endoparasiticide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Endoparasiticide market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Endoparasiticide significant trends, drivers, influence factors in global and regions.
6. To analyze Endoparasiticide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endoparasiticide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endoparasiticide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endoparasiticide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Endoparasiticide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endoparasiticide industry.
Chapter 3: Detailed analysis of Endoparasiticide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Endoparasiticide in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Endoparasiticide Sales Value (2020-2031)
- 1.2.2 Global Endoparasiticide Sales Volume (2020-2031)
- 1.2.3 Global Endoparasiticide Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Endoparasiticide Market Dynamics
- 2.1 Endoparasiticide Industry Trends
- 2.2 Endoparasiticide Industry Drivers
- 2.3 Endoparasiticide Industry Opportunities and Challenges
- 2.4 Endoparasiticide Industry Restraints
- 3 Endoparasiticide Market by Company
- 3.1 Global Endoparasiticide Company Revenue Ranking in 2024
- 3.2 Global Endoparasiticide Revenue by Company (2020-2025)
- 3.3 Global Endoparasiticide Sales Volume by Company (2020-2025)
- 3.4 Global Endoparasiticide Average Price by Company (2020-2025)
- 3.5 Global Endoparasiticide Company Ranking (2023-2025)
- 3.6 Global Endoparasiticide Company Manufacturing Base and Headquarters
- 3.7 Global Endoparasiticide Company Product Type and Application
- 3.8 Global Endoparasiticide Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Endoparasiticide Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Endoparasiticide Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Endoparasiticide Market by Type
- 4.1 Endoparasiticide Type Introduction
- 4.1.1 Ear Tags
- 4.1.2 Feed Additives
- 4.1.3 Tablets
- 4.1.4 Injectables
- 4.2 Global Endoparasiticide Sales Volume by Type
- 4.2.1 Global Endoparasiticide Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Endoparasiticide Sales Volume by Type (2020-2031)
- 4.2.3 Global Endoparasiticide Sales Volume Share by Type (2020-2031)
- 4.3 Global Endoparasiticide Sales Value by Type
- 4.3.1 Global Endoparasiticide Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Endoparasiticide Sales Value by Type (2020-2031)
- 4.3.3 Global Endoparasiticide Sales Value Share by Type (2020-2031)
- 5 Endoparasiticide Market by Application
- 5.1 Endoparasiticide Application Introduction
- 5.1.1 Veterinary Hospitals or Clinics
- 5.1.2 Home Care Settings
- 5.1.3 Animal Farms
- 5.2 Global Endoparasiticide Sales Volume by Application
- 5.2.1 Global Endoparasiticide Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Endoparasiticide Sales Volume by Application (2020-2031)
- 5.2.3 Global Endoparasiticide Sales Volume Share by Application (2020-2031)
- 5.3 Global Endoparasiticide Sales Value by Application
- 5.3.1 Global Endoparasiticide Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Endoparasiticide Sales Value by Application (2020-2031)
- 5.3.3 Global Endoparasiticide Sales Value Share by Application (2020-2031)
- 6 Endoparasiticide Regional Sales and Value Analysis
- 6.1 Global Endoparasiticide Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Endoparasiticide Sales by Region (2020-2031)
- 6.2.1 Global Endoparasiticide Sales by Region: 2020-2025
- 6.2.2 Global Endoparasiticide Sales by Region (2026-2031)
- 6.3 Global Endoparasiticide Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Endoparasiticide Sales Value by Region (2020-2031)
- 6.4.1 Global Endoparasiticide Sales Value by Region: 2020-2025
- 6.4.2 Global Endoparasiticide Sales Value by Region (2026-2031)
- 6.5 Global Endoparasiticide Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Endoparasiticide Sales Value (2020-2031)
- 6.6.2 North America Endoparasiticide Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Endoparasiticide Sales Value (2020-2031)
- 6.7.2 Europe Endoparasiticide Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Endoparasiticide Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Endoparasiticide Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Endoparasiticide Sales Value (2020-2031)
- 6.9.2 South America Endoparasiticide Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Endoparasiticide Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Endoparasiticide Sales Value Share by Country, 2024 VS 2031
- 7 Endoparasiticide Country-level Sales and Value Analysis
- 7.1 Global Endoparasiticide Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Endoparasiticide Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Endoparasiticide Sales by Country (2020-2031)
- 7.3.1 Global Endoparasiticide Sales by Country (2020-2025)
- 7.3.2 Global Endoparasiticide Sales by Country (2026-2031)
- 7.4 Global Endoparasiticide Sales Value by Country (2020-2031)
- 7.4.1 Global Endoparasiticide Sales Value by Country (2020-2025)
- 7.4.2 Global Endoparasiticide Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.9.2 France Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.16.2 China Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.19.2 India Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Endoparasiticide Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Endoparasiticide Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Endoparasiticide Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Comapny Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Novartis AG Endoparasiticide Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 Merck
- 8.2.1 Merck Comapny Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Merck Endoparasiticide Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Eli Lilly
- 8.3.1 Eli Lilly Comapny Information
- 8.3.2 Eli Lilly Business Overview
- 8.3.3 Eli Lilly Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Eli Lilly Endoparasiticide Product Portfolio
- 8.3.5 Eli Lilly Recent Developments
- 8.4 Bayer AG
- 8.4.1 Bayer AG Comapny Information
- 8.4.2 Bayer AG Business Overview
- 8.4.3 Bayer AG Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Bayer AG Endoparasiticide Product Portfolio
- 8.4.5 Bayer AG Recent Developments
- 8.5 Zoetis
- 8.5.1 Zoetis Comapny Information
- 8.5.2 Zoetis Business Overview
- 8.5.3 Zoetis Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Zoetis Endoparasiticide Product Portfolio
- 8.5.5 Zoetis Recent Developments
- 8.6 Virbac
- 8.6.1 Virbac Comapny Information
- 8.6.2 Virbac Business Overview
- 8.6.3 Virbac Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Virbac Endoparasiticide Product Portfolio
- 8.6.5 Virbac Recent Developments
- 8.7 Vetoquinol
- 8.7.1 Vetoquinol Comapny Information
- 8.7.2 Vetoquinol Business Overview
- 8.7.3 Vetoquinol Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Vetoquinol Endoparasiticide Product Portfolio
- 8.7.5 Vetoquinol Recent Developments
- 8.8 Elanco
- 8.8.1 Elanco Comapny Information
- 8.8.2 Elanco Business Overview
- 8.8.3 Elanco Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Elanco Endoparasiticide Product Portfolio
- 8.8.5 Elanco Recent Developments
- 8.9 Ceva Sante Animlae
- 8.9.1 Ceva Sante Animlae Comapny Information
- 8.9.2 Ceva Sante Animlae Business Overview
- 8.9.3 Ceva Sante Animlae Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Ceva Sante Animlae Endoparasiticide Product Portfolio
- 8.9.5 Ceva Sante Animlae Recent Developments
- 8.10 Boehringer Ingelheim
- 8.10.1 Boehringer Ingelheim Comapny Information
- 8.10.2 Boehringer Ingelheim Business Overview
- 8.10.3 Boehringer Ingelheim Endoparasiticide Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Boehringer Ingelheim Endoparasiticide Product Portfolio
- 8.10.5 Boehringer Ingelheim Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Endoparasiticide Value Chain Analysis
- 9.1.1 Endoparasiticide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Endoparasiticide Sales Mode & Process
- 9.2 Endoparasiticide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Endoparasiticide Distributors
- 9.2.3 Endoparasiticide Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.